Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 3.7% – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) dropped 3.7% on Thursday . The stock traded as low as $3.32 and last traded at $3.2450. Approximately 86,396 shares were traded during trading, a decline of 97% from the average daily volume of 2,562,198 shares. The stock had previously closed at $3.37.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wells Fargo & Company upped their price target on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Stock Down 3.1%

The firm has a market capitalization of $531.15 million, a price-to-earnings ratio of 20.38 and a beta of 0.18. The company has a fifty day moving average price of $2.63 and a two-hundred day moving average price of $1.56.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The business had revenue of $122.06 million for the quarter, compared to analysts’ expectations of $74.22 million. On average, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth approximately $25,000. Integrated Wealth Concepts LLC grew its position in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. R Squared Ltd increased its stake in Ironwood Pharmaceuticals by 286.5% in the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 28,735 shares during the period. Focus Partners Advisor Solutions LLC raised its position in Ironwood Pharmaceuticals by 284.6% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after buying an additional 29,409 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth $32,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.